Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study

Research output: Contribution to journalArticlepeer-review


  • John M S Bartlett
  • Kenneth J Bloom
  • Tammy Piper
  • Thomas J Lawton
  • Cornelis J H van de Velde
  • Douglas T Ross
  • Brian Z Ring
  • Robert S Seitz
  • Rodney A Beck
  • Annette Hasenburg
  • Dirk Kieback
  • Hein Putter
  • Christos Markopoulos
  • Luc Dirix
  • Caroline Seynaeve

Colleges, School and Institutes


Some postmenopausal patients with hormone-sensitive early breast cancer remain at high risk of relapse despite endocrine therapy and, in addition, might benefit from adjuvant chemotherapy. The challenge is to prospectively identify such patients. The Mammostrat test uses five immunohistochemical markers to stratify patients regarding recurrence risk and may inform treatment decisions. We tested the efficacy of this panel in the Tamoxifen versus Exemestane Adjuvant Multicenter (TEAM) trial.


Original languageEnglish
Pages (from-to)4477-84
Number of pages8
JournalJournal of Clinical Oncology
Issue number36
Publication statusPublished - 20 Dec 2012